Search research articles
Contact Us
Filters
Showing results (181-190 of 208) with videos related to
Page
of 21
Sort By:
Journal of Medical Virology
|
November 14, 2000
HIV-1 ICD p24 antigen detection in ugandan infants: use in early diagnosis of infection and as a marker of disease progression
L A Guay, D L Hom, S R Kabengera, et al.
AIDS (London, England)
|
September 13, 2000
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
J B Jackson, G Becker-Pergola, L A Guay, et al.
Pediatrics
|
September 1, 1996
Detection of human immunodeficiency virus type 1 (HIV-1) DNA and p24 antigen in breast milk of HIV-1-infected Ugandan women and vertical transmission
L A Guay, D L Hom, F Mmiro, et al.
Blood Cancer Journal
|
July 26, 2012
Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production
F L Khanim, B A M E Merrick, H V Giles, et al.
The New England Journal of Medicine
|
January 25, 1990
Absence of HIV infection in blood donors with indeterminate western blot tests for antibody to HIV-1
J B Jackson, K L MacDonald, J Cadwell, et al.
Journal of Acquired Immune Deficiency Syndromes
|
April 1, 1994
A phase I/II trial of intravenous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asymptomatic HIV-infected subjects
R C Kalayjian, G Skowron, R T Emgushov, et al.
The Journal of Infectious Diseases
|
May 24, 2001
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377)
S H Eshleman, P Krogstad, J B Jackson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 15, 2000
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks
C P Raines, C Flexner, E Sun, et al.
The Journal of Infectious Diseases
|
December 20, 2000
Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers
J M Jacobson, J S Greenspan, J Spritzler, et al.
AIDS (London, England)
|
October 16, 2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)
S H Eshleman, M Mracna, L A Guay, et al.
Page
of 21
Search research articles
Search
Showing results (181-190 of 208) with videos related to
Sort By:
Page
of 21
Journal of Medical Virology
|
November 14, 2000
HIV-1 ICD p24 antigen detection in ugandan infants: use in early diagnosis of infection and as a marker of disease progression
L A Guay, D L Hom, S R Kabengera, et al.
AIDS (London, England)
|
September 13, 2000
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
J B Jackson, G Becker-Pergola, L A Guay, et al.
Pediatrics
|
September 1, 1996
Detection of human immunodeficiency virus type 1 (HIV-1) DNA and p24 antigen in breast milk of HIV-1-infected Ugandan women and vertical transmission
L A Guay, D L Hom, F Mmiro, et al.
Blood Cancer Journal
|
July 26, 2012
Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production
F L Khanim, B A M E Merrick, H V Giles, et al.
The New England Journal of Medicine
|
January 25, 1990
Absence of HIV infection in blood donors with indeterminate western blot tests for antibody to HIV-1
J B Jackson, K L MacDonald, J Cadwell, et al.
Journal of Acquired Immune Deficiency Syndromes
|
April 1, 1994
A phase I/II trial of intravenous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asymptomatic HIV-infected subjects
R C Kalayjian, G Skowron, R T Emgushov, et al.
The Journal of Infectious Diseases
|
May 24, 2001
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377)
S H Eshleman, P Krogstad, J B Jackson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 15, 2000
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks
C P Raines, C Flexner, E Sun, et al.
The Journal of Infectious Diseases
|
December 20, 2000
Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers
J M Jacobson, J S Greenspan, J Spritzler, et al.
AIDS (London, England)
|
October 16, 2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)
S H Eshleman, M Mracna, L A Guay, et al.
Page
of 21